Research programme: amyotrophic lateral sclerosis gene therapy - Treeway

Drug Profile

Research programme: amyotrophic lateral sclerosis gene therapy - Treeway

Alternative Names: AAV5-GDNF gene therapy; ALS gene theapy - uniQure/Treeway; TW 002

Latest Information Update: 26 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator uniQure
  • Developer Treeway
  • Class Gene therapies; Nerve growth factors
  • Mechanism of Action Gene silencing; Gene transference; Glial cell line-derived neurotrophic factor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 26 Jan 2016 Preclinical trials in Amyotrophic lateral sclerosis in Netherlands (Parenteral)
  • 05 Jan 2016 Treeway plans the proof of concept clinical trial for Amyotrophic lateral sclerosis (Treeway pipeline, January 2016)
  • 15 Jan 2015 Early research in Amyotrophic lateral sclerosis in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top